Provided by Tiger Trade Technology Pte. Ltd.

EyePoint

5.01
+0.13502.77%
Post-market: 5.010.0050+0.10%19:47 EDT
Volume:4.13M
Turnover:21.03M
Market Cap:431.49M
PE:-1.33
High:5.29
Open:4.98
Low:4.96
Close:4.87
52wk High:19.11
52wk Low:3.95
Shares:86.21M
Float Shares:60.67M
Volume Ratio:0.46
T/O Rate:6.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7642
EPS(LYR):-3.1667
ROE:-148.70%
ROA:-74.85%
PB:2.59
PE(LYR):-1.58

Loading ...

Stifel Initiates EyePoint Pharmaceuticals at Buy With $40 Price Target

MT Newswires Live
·
Jul 16

Eyepoint Grants Inducement Stock Options for 63,500 Shares at $13.85 Each

Reuters
·
Jul 16

Eyepoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 16

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Jul 16

Eyepoint Inc : Stifel Initiates Coverage with Buy Rating; Target Price $40

THOMSON REUTERS
·
Jul 16

Eyepoint Pharmaceuticals Initiated at Buy by Stifel

Dow Jones
·
Jul 16

EyePoint initiated with a Buy at Stifel

TIPRANKS
·
Jul 16

EyePoint (EYPT) Adds Retina Leadership, Is The 64% Undervaluation Case Convincing?

Simply Wall St.
·
Jul 14

Mizuho Securities Remains a Buy on EyePoint Pharmaceuticals (EYPT)

TIPRANKS
·
Jul 13

Eyepoint Appoints Tarek S. Hassan, M.d., as Chief Strategic Science Officer

THOMSON REUTERS
·
Jul 13

Press Release: Eyepoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer

Dow Jones
·
Jul 13

Eyepoint Pharmaceuticals Coverage Assumed by Cantor Fitzgerald at Overweight

Dow Jones
·
Jul 08

Duravyu Pivotal Readout and Strong TKI Outlook Support Buy Rating; $43 Price Target Reiterated

TIPRANKS
·
Jul 06

Eyepoint Chief Medical Officer Ramiro Ribeiro Disposes of 4,875 Common Shares Worth $73,167.95

Reuters
·
Jul 03

Eyepoint Pharmaceuticals is Maintained at Buy by Chardan Capital

Dow Jones
·
Jul 01

Chardan Boosts Price Target on EyePoint Pharmaceuticals to $65 From $29, Keeps Buy Rating

MT Newswires Live
·
Jul 01

EyePoint price target raised to $65 from $29 at Chardan

TIPRANKS
·
Jul 01

Jefferies Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT)

TIPRANKS
·
Jun 25

Eyepoint Pharmaceuticals Price Target Maintained with a $68.00/share by Guggenheim

Dow Jones
·
Jun 24

Guggenheim Sticks to Its Buy Rating for EyePoint Pharmaceuticals (EYPT)

TIPRANKS
·
Jun 24